Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
59M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
36.7M
-
Shares change
-
+4.48M
-
Total reported value, excl. options
-
$395M
-
Value change
-
+$48.7M
-
Put/Call ratio
-
11.39
-
Number of buys
-
52
-
Number of sells
-
-56
-
Price
-
$10.76
Significant Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) as of Q2 2023
123 filings reported holding CGEM - Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.7M shares
of 59M outstanding shares and own 62.24% of the company stock.
Largest 10 shareholders include BIOIMPACT CAPITAL LLC (7.65M shares), CHI Advisors LLC (3.41M shares), BVF INC/IL (3.2M shares), FRANKLIN RESOURCES INC (2.33M shares), BlackRock Inc. (2.1M shares), VANGUARD GROUP INC (2.03M shares), BRAIDWELL LP (1.91M shares), AMERICAN INTERNATIONAL GROUP, INC. (1.24M shares), Nextech Invest Ltd. (1.22M shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (1.15M shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.